Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
NCT05194540
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
136
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Tralokinumab
Sponsor
LEO Pharma